Dale B Schenk

Summary

Affiliation: Elan Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning
    Dale Schenk
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA
    Nat Rev Neurosci 3:824-8. 2002
  2. ncbi request reprint Treatment of Alzheimer's disease: the beginning of a new era
    Dale Schenk
    Chief Scientific Officer, Elan Corporation, 800 Gateway Blvd, South San Francisco, CA 9480, USA
    Curr Alzheimer Res 3:177. 2006
  3. ncbi request reprint The role of microglia in Alzheimer's disease: friend or foe?
    D B Schenk
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, USA
    Neurobiol Aging 23:677-9; discussion 683-4. 2002
  4. ncbi request reprint Current progress in beta-amyloid immunotherapy
    Dale Schenk
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA
    Curr Opin Immunol 16:599-606. 2004
  5. ncbi request reprint A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease
    Dale B Schenk
    Elan Pharmaceuticals, San Francisco, CA 94080, USA
    Neurodegener Dis 2:255-60. 2005
  6. ncbi request reprint Commentary on "New directions for frontotemporal dementia drug discovery." Do we know enough to develop meaningful treatments for frontotemporal dementia?
    Dale Schenk
    Elan Pharmaceuticals, South San Francisco, CA, USA
    Alzheimers Dement 4:94-5. 2008
  7. doi request reprint Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course
    Dale Schenk
    Elan Pharmaceuticals, South San Francisco, CA, USA
    Alzheimers Dement 4:S119-21. 2008
  8. ncbi request reprint What do people at risk for Alzheimer disease think about surrogate consent for research?
    Dale B Schenk
    Neurology 66:1785-6. 2006

Detail Information

Publications8

  1. ncbi request reprint Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning
    Dale Schenk
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA
    Nat Rev Neurosci 3:824-8. 2002
  2. ncbi request reprint Treatment of Alzheimer's disease: the beginning of a new era
    Dale Schenk
    Chief Scientific Officer, Elan Corporation, 800 Gateway Blvd, South San Francisco, CA 9480, USA
    Curr Alzheimer Res 3:177. 2006
  3. ncbi request reprint The role of microglia in Alzheimer's disease: friend or foe?
    D B Schenk
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, USA
    Neurobiol Aging 23:677-9; discussion 683-4. 2002
  4. ncbi request reprint Current progress in beta-amyloid immunotherapy
    Dale Schenk
    Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA
    Curr Opin Immunol 16:599-606. 2004
    ..Abeta immunotherapy is also raising new opportunities and questions about the general role of the immune system in neurodegenerative diseases...
  5. ncbi request reprint A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease
    Dale B Schenk
    Elan Pharmaceuticals, San Francisco, CA 94080, USA
    Neurodegener Dis 2:255-60. 2005
    ..These findings have led to newer alternative A beta immunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe...
  6. ncbi request reprint Commentary on "New directions for frontotemporal dementia drug discovery." Do we know enough to develop meaningful treatments for frontotemporal dementia?
    Dale Schenk
    Elan Pharmaceuticals, South San Francisco, CA, USA
    Alzheimers Dement 4:94-5. 2008
  7. doi request reprint Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course
    Dale Schenk
    Elan Pharmaceuticals, South San Francisco, CA, USA
    Alzheimers Dement 4:S119-21. 2008
    ..Perhaps it is time to consider a similar approach in treatment of Alzheimer's disease...
  8. ncbi request reprint What do people at risk for Alzheimer disease think about surrogate consent for research?
    Dale B Schenk
    Neurology 66:1785-6. 2006